Tenaya Therapeutics (TNYA) Amortization of Deferred Charges (2021 - 2026)

Tenaya Therapeutics' Amortization of Deferred Charges history runs 6 years deep, the most recent figure standing at $654000.0 for Q1 2026.

• On a quarterly basis, Amortization of Deferred Charges rose 9.73% year-over-year to $654000.0 in Q1 2026; TTM through Mar 2026 was $2.5 million, a 20.53% decrease from a year earlier, with the FY2025 full-year figure at $2.5 million, down 27.07% from the prior year.
• Amortization of Deferred Charges rose to $654000.0 in Q1 2026 per TNYA's latest filing, from $640000.0 in the prior quarter.
• Across five years, Amortization of Deferred Charges topped out at $1.0 million in Q3 2024 and bottomed at $332000.0 in Q1 2022.
• The 5-year median for Amortization of Deferred Charges is $736000.0 (2022), against an average of $699764.7.
• Across the five-year window, Amortization of Deferred Charges jumped 131.39% in 2022 and sank 39.32% in 2025, its largest moves.
• Year by year, Amortization of Deferred Charges stood at $736000.0 in 2022, then grew by 9.51% to $806000.0 in 2023, then retreated by 8.68% to $736000.0 in 2024, then decreased by 13.04% to $640000.0 in 2025, then advanced by 2.19% to $654000.0 in 2026.
• Per Business Quant, the three latest TNYA Amortization of Deferred Charges figures stand at $654000.0 (Q1 2026), $640000.0 (Q4 2025), and $625000.0 (Q3 2025).